Want to see IN:GLENMARK full AI Analyst Report?
Top Page
Glenmark Pharmaceuticals Limited
(GLENMARK)
Select Model
Select Model
Rating:66Neutral
Price Target:
₹2,358.00
▲(14.14% Upside)
Action:Reiterated
Date:09/06/26
The score is driven primarily by improved financial performance (notably a stronger FY2026 and a much less leveraged balance sheet) and supportive technical momentum (price above key moving averages with positive MACD). Offsetting these positives are inconsistent cash-flow history and a relatively expensive valuation (high P/E with a very low dividend yield).
Positive Factors
Steady Revenue Growth
Sustained revenue expansion indicates Glenmark is increasing the scale of its branded, generic, and API businesses across its markets. Continued top-line growth can support operating leverage, broaden the earnings base, and provide resources for product development and commercial investment over the coming quarters.
Negative Factors
Earnings Volatility
The sharp swing from profit to a large loss and back to profit shows that Glenmark's earnings quality and consistency are not yet fully established. Such volatility makes future performance harder to underwrite and can constrain dependable planning, reinvestment, and shareholder-return decisions.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Sustained revenue expansion indicates Glenmark is increasing the scale of its branded, generic, and API businesses across its markets. Continued top-line growth can support operating leverage, broaden the earnings base, and provide resources for product development and commercial investment over the coming quarters.
Read all positive factors
Glenmark Pharmaceuticals Limited (GLENMARK) vs. iShares MSCI India ETF (INDA)
Market Cap
₹622.31B
Dividend Yield0.23%
Average Volume (3M)17.28K
Price to Earnings (P/E)34.4
Beta (1Y)0.54
Revenue Growth32.94%
EPS Growth138.54%
CountryIN
Employees16,946
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)48.26
Shares Outstanding282,224,670
10 Day Avg. Volume14,997
30 Day Avg. Volume17,279
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)5.72
Price to Sales (P/S)3.54
P/FCF Ratio30.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)80.9
Revenue Forecast (FY)₹167.99B
Glenmark Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, L...
How the Company Makes Money
Glenmark makes money primarily by selling pharmaceutical formulations (finished dosage medicines) and, to a lesser extent, APIs. Its revenue model is product-sales driven, with earnings generated when it supplies medicines to healthcare channels (...
Glenmark Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
80
Positive
Cash Flow
58
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 169.83B | 133.63B | 126.45B | 116.56B | 123.05B |
| Gross Profit | 80.84B | 88.38B | 80.66B | 72.45B | 77.57B |
| EBITDA | 27.67B | 23.93B | 20.77B | 17.49B | 23.27B |
| Net Income | 13.62B | 10.47B | -15.02B | 2.97B | 9.42B |
Balance Sheet | |||||
| Total Assets | 199.08B | 160.50B | 143.59B | 193.72B | 170.83B |
| Cash, Cash Equivalents and Short-Term Investments | 11.85B | 17.12B | 16.64B | 11.73B | 14.43B |
| Total Debt | 5.94B | 24.73B | 12.31B | 46.08B | 39.62B |
| Total Liabilities | 93.96B | 72.00B | 65.11B | 95.32B | 76.45B |
| Stockholders Equity | 105.12B | 88.49B | 78.48B | 94.74B | 90.87B |
Cash Flow | |||||
| Free Cash Flow | 19.41B | -15.77B | -11.64B | 176.29M | 3.19B |
| Operating Cash Flow | 32.99B | -8.28B | -2.65B | 6.25B | 11.09B |
| Investing Cash Flow | -13.25B | 20.94M | 45.44B | -5.28B | -3.33B |
| Financing Cash Flow | -25.21B | 7.87B | -39.06B | -774.56M | -5.20B |
Glenmark Pharmaceuticals Limited Technical Analysis
Negative
2065.95
Price Trends
2355.41
Negative
2282.90
Negative
2214.85
Negative
Market Momentum
-47.29
Positive
34.71
Neutral
36.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLENMARK, the sentiment is Negative. The current price of 2065.95 is below the 20-day moving average (MA) of 2294.87, below the 50-day MA of 2355.41, and below the 200-day MA of 2214.85, indicating a bearish trend. The MACD of -47.29 indicates Positive momentum. The RSI at 34.71 is Neutral, neither overbought nor oversold. The STOCH value of 36.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:GLENMARK.
Glenmark Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₹929.24B | 24.67 | ― | 0.25% | 9.09% | 9.61% | |
69 Neutral | ₹1.03T | 31.33 | ― | 0.65% | -0.92% | -41.74% | |
69 Neutral | ₹893.43B | 16.23 | ― | 0.92% | 28.19% | 49.25% | |
69 Neutral | ₹4.19T | 34.62 | ― | 0.92% | 11.41% | 16.62% | |
66 Neutral | ₹622.31B | 34.44 | ― | 0.23% | 32.94% | 138.54% | |
57 Neutral | ₹1.11T | 24.90 | ― | 0.09% | 21.11% | -1.28% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,183.10
335.09
18.13%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,626.00
527.05
47.96%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,239.00
-32.79
-2.58%
IN:LUPIN
Lupin Limited
1,928.00
1.92
0.10%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,753.95
80.24
4.79%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
1,135.00
128.11
12.72%
Glenmark Pharmaceuticals Limited Corporate Events
Glenmark expands U.S. dermatology reach with Adapalene pump-pack launch
Oct 6, 2026
Glenmark Therapeutics Inc., USA has launched new pump-pack formats of Adapalene Gel USP, 0.1% (OTC), a topical acne treatment positioned as comparable to the active ingredient in Differin Gel 0.1%. The product is now available via major online ret...
Glenmark Pharma Closes Trading Window Ahead of Q2 FY27 Results
Sep 28, 2026
Glenmark Pharmaceuticals has announced the closure of its trading window for designated persons, including directors, key managerial personnel, identified employees, their immediate relatives, and other connected persons, starting October 1, 2026....
Glenmark’s Goa Plant Secures U.S. FDA EIR With VAI Status
Sep 23, 2026
Glenmark Pharmaceuticals, a research-led global drugmaker with a strong footprint in respiratory, dermatology, and oncology therapies, operates 11 manufacturing plants worldwide and six RD centres, supplying branded, generic, innovative, and consu...
Glenmark to Meet Analysts and Investors at Emerging Titans 2026 Conference
Sep 21, 2026
Glenmark Pharmaceuticals has notified the stock exchanges that it will participate in the PL Capital Emerging Titans 2026 Conference in Mumbai on September 29, 2026, engaging with analysts and institutional investors through both group and one-on-...
India Ratings Lifts Glenmark Pharmaceuticals to ‘IND AA+’ on Stronger Balance Sheet
Sep 11, 2026
India Ratings and Research has upgraded Glenmark Pharmaceuticals’ long-term bank loans to ‘IND AA+’ with a Stable outlook, while affirming its short-term facilities at ‘IND A1+’. The upgrade covers existing and additi...
Glenmark Enters $70 Million U.S. Calcium Gluconate Market With New Injectables Launch
Aug 21, 2026
Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in three presentations – 1,000 mg/10 mL and 5,000 mg/50 mL single-dose vials, and a 10,000 mg/100 mL pharmacy bulk package – for the U.S. market. The produ...
Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray
Aug 20, 2026
Glenmark Pharmaceuticals has secured U.S. FDA approval for its Fluticasone Propionate Nasal Spray USP, 0.05 mg per spray, a generic version deemed bioequivalent and therapeutically equivalent to Haleon’s branded Flonase Nasal Spray. The prod...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.